Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 3Neoplasm Metastasis 2Skin Neoplasms 1

Interventions

pembrolizumab 36Cyclophosphamide 24Nivolumab 23Ipilimumab 22aldesleukin 19Interleukin-2 15fludarabine 14Specimen Handling 12Dacarbazine 11fludarabine phosphate 10Magnetic Resonance Spectroscopy 10Temozolomide 9Radiosurgery 9Biopsy 9cemiplimab 8Paclitaxel 8dabrafenib 5binimetinib 5Vemurafenib 5Radiotherapy 5Carboplatin 5trametinib 4sargramostim 4encorafenib 4avelumab 4Pemetrexed 4Leucovorin 4Fluorouracil 4Cisplatin 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Interleukins × Dermatologic × Clear all
NCT01856023 2023-12-05

PROCLIVITY02

Clinigen, Inc.

Phase 4 Terminated
29 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

University Health Network, Toronto

Phase 2 Completed
12 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡